Trevena (NASDAQ:TRVN) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Trevena (NASDAQ:TRVNFree Report) in a research note released on Friday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Trevena Stock Performance

Shares of Trevena stock opened at $0.46 on Friday. The business has a 50-day moving average of $0.57 and a 200 day moving average of $0.61. Trevena has a 12 month low of $0.41 and a 12 month high of $3.28. The stock has a market capitalization of $8.43 million, a price-to-earnings ratio of -0.16 and a beta of 1.13. The company has a debt-to-equity ratio of 8.35, a current ratio of 6.41 and a quick ratio of 6.27.

Hedge Funds Weigh In On Trevena

Hedge funds and other institutional investors have recently bought and sold shares of the company. Jane Street Group LLC purchased a new position in Trevena during the 2nd quarter valued at about $25,000. Jump Financial LLC acquired a new stake in Trevena in the 3rd quarter valued at about $27,000. Dimensional Fund Advisors LP acquired a new stake in Trevena in the 4th quarter valued at about $40,000. Renaissance Technologies LLC raised its position in Trevena by 51.8% in the 1st quarter. Renaissance Technologies LLC now owns 70,532 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 24,080 shares in the last quarter. Finally, Virtu Financial LLC acquired a new stake in Trevena in the 2nd quarter valued at about $70,000. 13.56% of the stock is currently owned by hedge funds and other institutional investors.

Trevena Company Profile

(Get Free Report)

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.

See Also

Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.